Novel Targeted Therapies for Esophagogastric Cancer

被引：23

作者：

Maron, Steven B. ^{[1
]}

Catenacci, Daniel V. T. ^{[1
]}

机构：

[1] Univ Chicago, Ctr Comprehens Canc, Sect Hematol Oncol, 900 E 57th St,Suite 7128, Chicago, IL 60637 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2017年 / 26卷 / 02期

关键词：

Gastric cancer; Esophagogastric junction cancer; Gastroesophageal adenocarcinoma; HER2; VEGFR2; EGFR; MET; FGFR2; ADVANCED GASTRIC-CANCER; PHASE-II TRIAL; GROWTH-FACTOR RECEPTOR; CETUXIMAB PLUS OXALIPLATIN/LEUCOVORIN/5-FLUOROURACIL; HER2 GENE AMPLIFICATION; DOUBLE-BLIND; GASTROESOPHAGEAL JUNCTION; OPEN-LABEL; C-MET; PROGNOSTIC-SIGNIFICANCE;

D O I：

10.1016/j.soc.2016.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) is increasing in incidence. GEC, including GC and EGJ, is treated uniformly in the metastatic setting. Overall survival in the metastatic setting remains poor. Molecular characterization of GEC has identified mutations and copy number variations, along with other oncogenes, biomarkers, and immuno-oncologic checkpoints that may serve as actionable therapeutic targets. This article reviews these key aberrations, their impact on protein expression, therapeutic implications, and clinical directions within each pathway.

引用

页码：293 / +

页数：21

共 110 条

[1] Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies [J].

Ali, Siraj M. ;

Sanford, Eric M. ;

Klempner, Samuel J. ;

Rubinson, Douglas A. ;

Wang, Kai ;

Palma, Norma A. ;

Chmielecki, Juliann ;

Yelensky, Roman ;

Palmer, Gary A. ;

Morosini, Deborah ;

Lipson, Doron ;

Catenacci, Daniel V. ;

Braiteh, Fadi ;

Erlich, Rachel ;

Stephens, Philip J. ;

Ross, Jeffrey S. ;

Ou, Sai-Hong Ignatius ;

Miller, Vincent A. .

ONCOLOGIST, 2015, 20 (05) :499-507

[2]